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Are A-Bomb Survivor Studies
an Appropriate Basis for
Nuclear Worker
Compensation?
Wakeford (2003) and Little (2003) wrote
in response to our comments about the use
of A-bomb survivor studies as a basis for
U.S. nuclear worker compensation deci-
sions (Wing and Richardson 2002). 
Wakeford (2003) disagrees with our
statement (Wing and Richardson 2002)
that there is discrepancy between childhood
cancer risk estimates from in utero radiation
in A-bomb and diagnostic X-ray studies.
Doll and Wakeford (1997) stated that
“children exposed in utero to radiation from
atomic bomb explosions have not experi-
enced any corresponding risk of cancer,”
the discrepancy “being the most serious rea-
son for doubt” about findings from the
Oxford Survey of Childhood Cancers
(OSCC) (Stewart et al. 1956; Bithell 1993),
the first and largest study to demonstrate
the link between childhood cancer and in
utero irradiation. Doll and Wakeford (1997)
concluded, 
only one reason would appear to be serious:
namely lack of any comparable excess in cohorts
of children irradiated in utero, most notably in
those exposed to radiation from the explosion of
the atomic bombs in Japan.
Although we raised questions about
potential sources of bias in the A-bomb
data, Wakeford (2003) argues that risk esti-
mates for the in utero cohort of A-bomb sur-
vivors are “compatible with” findings from
the OSCC, given the imprecision of these
estimates. There are indeed few childhood
cancers among those exposed in utero.
However, the OSCC suggests approximately
a 40% excess of childhood cancers following
exposure to a prenatal X ray, the majority of
cases being childhood leukemias (Bithell
1993). The work of McMahon et al. (1962)
supports this finding but suggests an excess
exclusively of childhood leukemia (Bithell
1993). In contrast, among Japanese sur-
vivors exposed in utero, there were no child-
hood leukemias and no childhood cancers
before the age of 10 years (the age range of
most OSCC cases). One case of childhood
cancer in a 10-year-old has been reported
(nephroblastoma) and a second case was
reported in a 14-year-old (hepatoma) (Kato
et al. 1989; Yoshimoto et al. 1988, 1991).
Wakeford (2003) argues that, based on
these two cases, a dose–response estimate for
childhood cancer occurring at ages < 15
years following in utero exposure is compati-
ble with, although smaller than, the effect
estimate derived using OSCC data. More
than imprecision, the absence of childhood
leukemia and childhood cancers before 10
years of age may be indicative of selection
bias in the A-bomb cohort (Stewart 2000). 
Little (2003) wrote that uncertainties in
external radiation dose estimates for
A-bomb survivors are of comparable magni-
tude to those for badge-monitored nuclear
industry workers. Because there was no
instrumentation in place for measuring the
survivors’ doses at the time of exposure, sur-
vivors’ dose estimates rely on information
derived from a questionnaire. Therefore,
issues related to the survey administration
are fundamental to the accuracy of these
data. The survey was conducted under
direction of an occupying military force
(Lindee 1994). Respondents had experi-
enced a nuclear holocaust and potentially
were suffering posttraumatic stress disorder.
It is suspected that not all survivors truth-
fully reported their proximity to the epi-
centers of the bombings (Watts 2000).
Estimates of uncertainty in radiation doses
derived under simple statistical assump-
tions about the distributions of errors do
not account for such problems.
Little (2003) also questioned concerns
about selective survival in the A-bomb study.
Shimizu et al. (1999) described evidence of
selective survival in the Life Span Study
based on analyses of noncancer mortality,
and Stewart and Kneale (2000) noted differ-
ences in radiation-mortality dose–response
relationships among survivors with and with-
out reports of acute injuries, suggesting evi-
dence of selective survival. Little’s assertion
that simple assumptions about errors in dose
estimates reduce the statistical significance of
differences in dose–response relationships
between these groups (Little 2003) is
premised on a misplaced reliance on statisti-
cal significance testing. Furthermore, Little
fails to address Stewart and Kneale’s central
premise (Stewart and Kneale 2000): selec-
tion effects varied with age, being greatest
for the very old and the young at the time of
bombing. Stewart (2000) argued that a
more pronounced survival of the fittest at
the extremes of age has influenced evidence
of radiation effects. 
Critical evaluation of potential sources of
bias in the A-bomb studies is timely because
of proposals that this study provide the basis
for judgments in worker compensation. 
The authors declare they have no conflict of
interest.
David Richardson
Steve Wing
Department of Epidemiology
School of Public Health
University of North Carolina
Chapel Hill, North Carolina
E-mail: david_richardson@unc.edu
REFERENCES
Bithell JF. 1993. Statistical issues in assessing the evidence
associating obstetric irradiation and childhood malignancy.
In: Neue Bewertung des Strahlenriskos: Niedrigdosis-
Strahlung und Gesundheit (Lengfelder E, Wendhausen H,
eds). Munich:MMV Medizin Verlag, 53–60.
Doll R, Wakeford R. 1997. Risk of childhood cancer from fetal
irradiation. Br J Radiol 70:130–139.
Kato H, Yoshimoto Y, Schull WJ. 1989. Risk of cancer among
children exposed to atomic bomb radiation in utero: a
review. IARC Sci Publ 96:365–374. 
Lindee MS. 1994. Suffering made real: American science and
the survivors at Hiroshima. Chicago, IL:University of
Chicago Press.
Little MP. 2003. Comment on “Use of A-bomb survivor studies
as a basis for nuclear worker compensation” [Letter].
Environ Health Perspect 111:A267–268.
McMahon B. 1962. Prenatal X-ray exposure and childhood
cancer. J Natl Cancer Inst 28:1173–1191. 
Shimizu Y, Pierce DA, Preston DL, Mabuchi K. 1999. Studies of
the mortality of atomic bomb survivors. Report 12, part II.
Noncancer mortality: 1950–1990. Radiat Res 152:374–389.
Stewart A. 2000. The role of epidemiology in the detection of
harmful effects of radiation. Environ Health Perspect
108:93–96.
Stewart AM, Kneale GW. 2000. A-bomb survivors: factors that
may lead to a re-assessment of the radiation hazard. Int
J Epidemiol 29:708–714.
Stewart AM, Webb J, Giles D, Hewitt D. 1956. Malignant dis-
eases in childhood and diagnostic irradiation in utero.
Lancet 2:447
Wakeford R. 2003. Re: “Use of A-Bomb Survivor Studies as a
Basis for Nuclear Worker Compensation” [Letter].
Environ Health Perspect 111:A268–A269.
Watts J. 2000. Japan’s hibakusha still battle the effects of US
nuclear bombs. Lancet 356:1009.
Wing S, Richardson D. 2002. Use of A-bomb survivor studies as
a basis for nuclear worker compensation [Letter]. Environ
Health Perspect 110:A739.
Yoshimoto Y, Kato H, Schull WJ. 1988. Risk of cancer among
children exposed in utero to A-bomb radiations, 1950-84.
Lancet 2:665–669.
———. 1991. A review of forty-five years study of Hiroshima
and Nagasaki atomic bomb survivors. Cancer risk among
in utero-exposed survivors. J Radiat Res 32:231–238.
Developmental Effects of
Herbicides in Mice
We would like to respond to criticisms of
our paper (Cavieres et al. 2002) raised by
Lamb et al. (2003) and Ashby et al. (2003)
in the July 2003 issue of EHP. The order of
our responses generally follow the sequence
in the letter by Ashby et al.
There were inadvertent numerical errors
in our data presentation but not in our
analysis. The corrections can be found in the
errata in this issue of EHP (111:A751). In
all cases the numerical errors are small in
magnitude, and most of them involve minor
differences in sample size. Our statistical
analysis and conclusions were based on the
correct data set and are not affected by these
presentation errors.
We regret that these small numerical
presentation errors shifted the focus of dis-
cussion from the broader implications of our
research. In Table 2 of our paper (Cavieres
et al. 2002), we showed that in all seasons
every treatment group had fewer young than
the control group. Only occasional points
were statistically significant. Only when we
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and a smaller standard error did the treat-
ment effects become significant. We con-
cluded that most researchers will find only
trends and not significant effects because
treatment group sample sizes in individual
experiments are too small.
Lamb et al. (2003) referred to discrepan-
cies between our paper (Cavieres et al. 2002)
and the PhD thesis by Cavieres (2001). The
analysis in our paper (Cavieres et al. 2002)
was performed on the original computer data
files, which we consider to be the ultimate
source. The thesis (Cavieres 2001) was based
on an earlier analysis of the data and contains
many other measurements not included in
our paper. The data presentation in the thesis
(Cavieres 2001) is based on exposure period
(preimplantation and organogenesis exposure
vs. organogenesis exposure only), whereas the
data presentation in our paper (Cavieres et al.
2002) is based on season. This makes it very
difficult to correctly compare data in the the-
sis with data in our paper, especially when
comparisons are made by people who are not
familiar with the whole work. 
We used analysis of covariance with lit-
ter size as a covariate to test the juvenile
weight and length data. This eliminated the
known decrease in juvenile weight and
length in larger litters and tested for the pos-
sible hidden effects of the pesticide doses.
When we tested the control litter distri-
bution, it was not significantly different
from normal (Kolmogorov-Smirnov test,
p = 0.54). Larger litters may have been trun-
cated to 12 either by loss of young during
pregnancy or by the females eating new-
borns before we could find and count them.
The important point shown in Figure 1 is
that the number of litters in every treatment
group is numerically smaller than the smallest
control litter. The version of Figure 1 in our
original article (Cavieres et al. 2002) did not
emphasize these differences as much as we
had hoped. Figure 2 in our paper (Cavieres et
al. 2002) was an attempt to show how this
difference in number occurred.
A major point of Lamb et al.’s (2003)
criticism of our paper involved our discus-
sion of the possible causes of decreased
implantation sites in treated animals shown
in our original Figure 2 (Cavieres et al.
2002). When we were considering possible
causes of embryo loss, we included loss dur-
ing the first days after implantation.
Implantation in mice does not occur only
on gestation day (GD) 5, but is a gradual
process occurring from GD4.5 to GD6
(Kaufman and Bard 1999). 
We detected implantation sites by stain-
ing the uterus for iron and viewing it under a
dissecting microscope. Embryos are not large
enough to leave a visible implantation-site
stain until about GD8. All our mice were
dosed from GD6 to GD15, with spring
mice additionally dosed on GD0–GD5.
This means that all females were exposed
during the first days after implantation
(GD6–GD8), when lost embryos would not
leave a visible implantation-site stain. The
significant losses in summer-experiment
mice strongly indicate that embryo losses
during GD6–GD8 caused the effects.
In Table 4 of our paper (Cavieres et al.
2002), every treatment group except for
the very-low-dose winter group also had
more resorptions than the control group.
Although these losses were not statistically
significant, they suggest that losses of
embryos continue to occur throughout
pregnancy. Both implantation and resorp-
tion data are plotted in the new Figure 1 as
difference from control: the decrease from
control in the case of implantations, and
the increase from control in the case of
resorptions. Again, implantation deficit
indicates a loss of embryos during early
pregnancy, and excess resorption indicates
a loss of embryos during later pregnancy.
Figure 1 clearly shows a loss of embryos in
all groups during pregnancy.
Both Lamb et al. (2003) and Ashby et
al. (2003) criticized our presentation of data
on a seasonal basis. We used this presenta-
tion not to promote a discussion of seasonal
effects but rather to show the entire data set
without showing each individual experi-
ment. We chose to let the reader judge our
data for themselves.
Ashby et al. (2003) criticized our merging
of birth data to generate our Figure 2
(Cavieres et al. 2002). This figure was drawn
primarily to show resorptions—the difference
between implantations and births. To do this
accurately, we had to use the births from the
litters for which we had implantation data.
The consistency of our data over the various
seasons (Table 2; Cavieres et al. 2002) justi-
fies combining the data for the final analysis.
Notice that three of the four seasons plotted
by Ashby et al. in their Figure 1 (Ashby et al.
2003) show a U-shaped response in births.
This resorption data is shown much more
effectively in our new Figure 1.
We take special exception to the infer-
ence by Ashby et al. (2003) that mice can
use only visual cues to detect season; they
forgot subtle but significant aspects of ani-
mal biology and natural history. Mice have
many senses other than vision, and their
senses are far better than ours, especially
olfaction, which can detect pollen, the smell
of rain, and other seasonal fragrances. There
are many cues available for animals to detect
season, even in our light-tight animal-care
facilities. For example, immune responses
determined in laboratory conditions are
affected by seasonal influences, with a lower
response usually occurring during winter
months, although this sensitivity to winter
depends on the strain (Dozier et al 1997;
Ratajczak et al 1993).
Lamb et al. (2003) criticized our discus-
sion that our data may follow an inverted
dose–response curve. In criticizing our dis-
cussion, they tried to minimize the
enhanced effect on decreased litter size at
the low end of the dose range, a response
that does not follow the classical linear
dose–response relationship. Inverted dose
responses have been observed for some time
in both dose responses to hormones and to
radiation. Inverted dose responses also have
been documented for endocrine, immune,
and neurologic responses to pesticides and
other environmental contaminants (Olson
et al. 1987; Levin et al. 2002; Welshons et
al. 2003). 
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Figure 1. Implantation deficit and resorption
excess plotted as difference from control.
Implantation deficit is a decrease from control,
while resorption excess is an increase from con-
trol. Implantation deficit indicates a loss of
embryos during early pregnancy, and resorption
excess indicates a loss of embryos during later
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Ethics of Pesticide Testing in
Humans
With some dismay, we read the article by
Meaklim et al. titled “Fenitrothion:
Toxicokinetics and Toxicologic Evaluation in
Human Volunteers” that appeared in the March
2003 issue of EHP (Meaklim et al. 2003).
The ethical aspects of testing pesticides
in humans have been the subject of vigor-
ous recent debate. A committee has been
convened at the National Academy of
Sciences to consider the issue. Our Center
for Children’s Health and the Environment
at the Mount Sinai School of Medicine
held a national conference in 2002 on the
ethical aspects of pesticide testing in
humans (Conference on Pesticide Testing
in Humans: Ethics and Public Policy, held
27 February 2002, New York, NY).
A fundamental problem is that no fed-
erally mandated ethical standards exist for
safeguarding volunteers in pesticide studies.
The U.S. Environmental Protection Agency
has never established such standards. This is
a situation very different from that which
exists in the case of clinical trials of drugs
conducted under the auspices of the Food
and Drug Administration.
A serious ethical impediment to pesti-
cide testing in humans is that there is no
conceivable way in which the administration
of a pesticide to a person can benefit the
health of that person. The logic that permits
controlled clinical trials of pharmacologic
agents that may directly benefit human
health does not pertain here.
We strongly recommend that EHP adopt
an explicit policy for the consideration of
future manuscripts that might involve testing
pesticides in human volunteers. We specifi-
cally suggest that no further papers involving
testing of pesticides in humans be accepted
until federal policy on pesticide testing in
humans has been clarified.
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Ethics of Pesticide Testing:
Response
We thank Landrigan et al. for raising the
important issue of ethics in relation to
human studies of pesticide exposure. This
issue was considered in great detail before
we began our study with fenitrothion. We
agree that ethical standards should be devel-
oped as soon as possible to protect the
safety of volunteers and the broader public
health needs of the community.
Landrigan et al. consider the fundamen-
tal issue to be that our volunteers were
administered a substance that could “… in
no conceivable way … benefit the health of
that person.” They state that, in this respect,
our studies differ from more ethically
acceptable studies of pharmacologic agents
in humans.
In our view, this comparison is not
appropriate because a high proportion of
drug-related research, especially in early
phase studies, involves volunteers who gain
no benefit from their participation.
Our study was subjected to extensive
ethical review by an institutional ethics com-
mittee. The role of this committee was to
make an independent determination about
the acceptability of the risks to the study par-
ticipants and whether the risks were appro-
priately explained in the documentation
provided to them. A secondary issue was
whether the study itself could be justified in
the context of community benefit. These
are considerations applied to all volunteer
studies, including those for new drugs.
Before approving this study, the
Institutional Ethics Committee of Monash
University went further by seeking outside
scientific advice and requiring an indepen-
dent expert clinician be available to counsel
volunteers. The participants were mostly
individuals with medical or scientific quali-
fications, and several had a specific knowl-
edge of pesticide toxicology. A. McLean
and I (J.J.M.) were the first participants to
be studied.
One important issue to consider is
whether it is ethical to expose large human
populations to pesticide residues without
specific knowledge of the way the agents are
handled by humans, or reassurance about
an adequate safety margin between expo-
sure levels and adverse effects. A reasonable
attitude is that studies involving informed
and consenting volunteers, who are exposed
to controlled low doses of the agents in
question and carefully monitored for ill
effects, are more ethically acceptable than
exposing whole populations without the
reassurance provided by this information.
Our study (Meaklim et al. 2003) was
undertaken because, at the time, fenitroth-
ion was the principal pesticide residue to
which this population was exposed. The
study, undertaken in accordance with the
highest ethical standards, could contribute
to the model Landrigan et al. believe should
be established by the U.S. Environmental
Protection Agency.
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CORRECTIONS
In “Developmental Toxicity of a Commercial Herbicide Mixture in Mice: I. Effects on
Embryo Implantation and Litter Size” [Environ Health Perspect 110:1081–1085 (2002)], by
Cavieres et al., some values in Tables 2 and 3 were incorrect.
In Table 3, the correct weight (mean ± SD) for control/winter is 1.43 ± 0.15 (n=17). 
Table 2 is shown below; values that have been corrected from the original table are
shown in boldface.
The authors regret the errors.
In Figure 4B of “Diminished Experience-Dependent Neuroanatomical Plasticity:
Evidence for an Improved Biomarker of Subtle Neurotoxic Damage to the Developing
Rat Brain” by Wallace et al. [Environ Health Perspect 111:1294–1298 (2003)], the 
x-axis labels were incorrect. The corrected figure is shown below.
EHP regrets the error.
The September Headliners article “Sperm Abnormalities in Men Exposed to PCBs and
PCDFs” [Environ Health Perspect 111:A639 (2003)] incorrectly suggests that Yucheng
is a geographic name when in fact it is the name (meaning “oil disease”) for the infamous
1979 contaminated cooking oil incident. EHP regrets the error.
Table 2. Litter size in females exposed to a commercial mixture of 2,4-D, mecoprop, and dicamba during
pregnancy in different seasons [mean ± SD (n)].
Dose Fall Winter Spring Summer
Control 11.4 ± 1.3 (18) 10.8 ± 1.1 (17) 11.0 ± 1.5 (15) 10.6 ± 1.5 (12)
Very low  ND 9.2 ± 1.8 (19)** ND 8.2 ± 2.2 (12)**
Low 10.5 ± 1.5 (14) 9.4 ± 1.4 (11) 9.4 ± 1.9 (18)** 7.7 ± 2.3 (15)*
Intermediate 9.4 ± 1.5 (18) 8.9 ± 2.0 (14)* 9.5 ± 1.9 (17) 9.3 ± 1.6 (12)
High 8.8 ± 1.6 (18)* 9.9 ± 1.9 (13) 10.3 ± 1.9 (19) 9.9 ± 1.0 (13)
ND, not determined. Pregnant mice were exposed during organogenesis (GD5–15) except for the spring experiment,
when they were exposed during preimplantation and organogenesis (GD0–15).
*p < 0.05; **p < 0.01, ANCOVA, Bonferroni. 
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